抗击纤维化的黄类药物:准NF-κB信号,并以为支持
Haitham Amin1, Hanan S Althagafy2, Mostafa S Abd El-Maksoud3
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Chemistry & biodiversity
|February 10, 2025
概括
黄类药物通过抑制NF-κB通路来对抗慢性病 (CKD) 和纤维化. 这些天然化合物显示出显著的抗纤维素作用,为病患者提供了有前途的治疗途径.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 慢性病 (CKD) 是一个主要的健康问题,纤维化是末期病 (ESKD) 的关键驱动因素.
- 氧化应激和炎症是纤维化进展的主要原因,尽管确切的机制尚不清楚.
- 黄类,是一种植物性化合物,具有与疾病管理相关的已知的抗炎和抗氧化特性.
研究的目的:
- 在慢性病 (CKD) 的背景下,审查各种黄类药物的抗纤维素潜力.
- 阐明核因子kappa B (NF-κB) 信号传导在调解黄类药物对纤维化影响中的作用.
- 要突出显示特定的黄类药物对NF-κB激活具有强烈的抑制作用.
主要方法:
- 文献综述侧重于调查黄类药物,纤维化,氧化应激,炎症和NF-κB信号的研究.
- 在基研究的分析,研究了黄类药物与NF-κB的结合相互作用.
- 对针对纤维化的特定黄类药物的治疗疗效的综合证据.
主要成果:
- 许多类黄素,包括原蛋白,氨酸和氨酸,通过向NF-κB通路,表现出有前途的抗纤维素作用.
- 在分析证实,黄类药物通过各种分子相互作用与其活性部位结合,有效抑制NF-κB.
- 鉴定出西利比宁,拜卡林和拜卡林是NF-κB的特别强大的抑制剂.
结论:
- 黄类药物代表了通过抑制NF-κB信号传递来对抗纤维化和慢性病 (CKD) 的有希望的治疗策略.
- 用特定的黄类药物向NF-κB提供了一种潜在的途径,可以缓解损害的进展.
- 对基于黄类药物的治疗方法的进一步研究可能会为患有脏疾病的患者带来新的治疗方法.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.2K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
338
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
Renal Failure: Dose Adjustments
60
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
60
